Loading...
Is tofacitinib a game-changing drug for ulcerative colitis?
The increasing knowledge on ulcerative colitis’ pathophysiology has contributed to the expansion of the therapeutic arsenal for this condition. However, to date, 25–40% of patients with ulcerative colitis remain primary or secondary non-responders to therapy, and up to 10% need to eventually undergo...
Na minha lista:
| Udgivet i: | United European Gastroenterol J |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7435001/ https://ncbi.nlm.nih.gov/pubmed/32552501 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2050640620935732 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|